Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
PMID (25336117)
Authors Rechsteiner M, Wild P, Kiessling MK, Bohnert A, Zhong Q, Stahel RA, Moch H, Curioni-Fontecedro A
Title A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib.
Journal Annals of oncology : official journal of the European Society for Medical Oncology
Vol 26
Issue 1
Date 2015 Jan
Abstract Text


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
PDGFRB A6V missense unknown PDGFRB A6V lies within the signal peptide region of the Pdgfrb protein ( A6V has been identified in the scientific literature (PMID: 25336117), but has not been biochemically characterized and therefore, its effect on Pdgfrb protein function is unknown (PubMed, Sep 2022).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
PDGFRB A6V colorectal cancer predicted - sensitive Regorafenib Case Reports/Case Series Actionable In a clinical case study, a patient with metastatic colorectal cancer harboring germline PDGFRB A6V demonstrated a partial morphological and metabolic response after 8 weeks of treatment with Stivarga (regorafenib) and remained in partial remission with sustained clinical improvement for at least 9 months from the start of treatment (PMID: 25336117). 25336117